PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-51.09%
Negative revenue growth while 5715.T stands at 3.11%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-44.77%
Negative gross profit growth while 5715.T is at 6.39%. Joel Greenblatt would examine cost competitiveness or demand decline.
-95.27%
Negative EBIT growth while 5715.T is at 20.40%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-95.63%
Negative operating income growth while 5715.T is at 23.77%. Joel Greenblatt would press for urgent turnaround measures.
-93.52%
Negative net income growth while 5715.T stands at 69.27%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-93.52%
Negative EPS growth while 5715.T is at 69.28%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-93.52%
Negative diluted EPS growth while 5715.T is at 69.28%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
175.02%
10Y revenue/share CAGR above 1.5x 5715.T's 33.49%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
21.78%
5Y revenue/share CAGR at 75-90% of 5715.T's 24.90%. Bill Ackman would encourage strategies to match competitor’s pace.
21.42%
3Y revenue/share CAGR above 1.5x 5715.T's 9.78%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
131.42%
Similar net income/share CAGR to 5715.T's 140.79%. Walter Schloss would see parallel tailwinds or expansions for both firms.
128.41%
5Y net income/share CAGR above 1.5x 5715.T's 31.91%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
194.76%
3Y net income/share CAGR above 1.5x 5715.T's 60.84%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
138.64%
10Y equity/share CAGR at 75-90% of 5715.T's 160.10%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
51.28%
5Y equity/share CAGR at 50-75% of 5715.T's 77.13%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
31.75%
3Y equity/share CAGR at 50-75% of 5715.T's 48.53%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.18%
Firm’s AR is declining while 5715.T shows 4.28%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
23.38%
Inventory growth well above 5715.T's 9.81%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
4.02%
Asset growth 1.25-1.5x 5715.T's 3.07%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
3.97%
BV/share growth above 1.5x 5715.T's 0.05%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
17.57%
Debt growth far above 5715.T's 8.51%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-100.00%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-16.18%
We cut SG&A while 5715.T invests at 5.29%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.